Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus

被引:104
|
作者
Baraka, OZ
Mahmoud, BM
Marschke, CK
Geary, TG
Homeida, MMA
Williams, JF
机构
[1] UNIV KHARTOUM,FAC PHARM,DEPT PHARMACOL,KHARTOUM,SUDAN
[2] UPJOHN CO,KALAMAZOO,MI 49001
[3] MICHIGAN STATE UNIV,E LANSING,MI 48824
关键词
ivermectin; onchocerciasis; pharmacokinetics; tissue concentration; enterohepatic;
D O I
10.1007/s002280050131
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To determine the distribution of ivermectin in plasma and tissues of onchocerciasis patients following a single oral dose of 150 mu g kg(-1). Setting. Medical Department at Soba University Hospital, Khartoum. Patients: Twenty five patients and fourteen healthy volunteers. Methods: Serial blood samples were obtained from both groups. Tissue samples were removed from various patients as full thickness skin punch biopsies or during nodulectomy. Ivermectin concentration was determined by radioimmunoassay. Results: The plasma pharmacokinetic variables for patients were maximum plasma concentration 52.0 ng ml(-1) time to achieve maximum concentration, 5.2 h.; elimination half life, 35.0 h; and the area under the plasma concentration curve versus time, 2852 ng . h ml(-1). In healthy volunteers, the plasma ivermectin distribution was similar to that in patients, and both groups showed a tendency for a second rise in plasma concentration of the drug suggestive of enterohepatic recirculation. Ivermectin was detected in tissues obtained from patients. Fat showed the highest and most persistent levels, whilst values for skin, nodular tissues, and worms were comparable. Subcutaneous fascia contained the lowest concentrations. Conclusion: Infection with O. volvulus does not affect the pharmacokinetics of ivermectin, and filarial infected tissues and parasites themselves do take up the drug. There may be prolonged retention of ivermectin because of depot formation in fat tissue.
引用
收藏
页码:407 / 410
页数:4
相关论文
共 50 条
  • [41] The impact of bi-annual ivermectin mass drug administration on the level of endemicity and intensity of Onchocerca volvulus infection in Adansi South District of Ghana
    Antwi-Berko, D.
    Debrah, A. Y.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2015, 20 : 314 - 314
  • [42] IVERMECTIN-FACILITATED IMMUNITY IN ONCHOCERCIASIS - ACTIVATION OF PARASITE-SPECIFIC TH1 TYPE RESPONSES WITH SUBCLINICAL ONCHOCERCA-VOLVULUS INFECTION
    SOBOSLAY, PT
    LUDER, CGK
    HOFFMANN, WH
    MICHAELIS, I
    DREWECK, CM
    PRITZE, S
    WOLF, H
    BANLA, M
    SCHULZKEY, H
    PARASITE, 1994, 1 : 15 - 15
  • [43] Reduction in the prevalence and intensity of infection in Onchocerca volvulus microfilariae according to ethnicity and community after 8 years of ivermectin treatment on the island of Bioko, Equatorial Guinea
    Mas, J.
    Ascaso, C.
    Escaramis, G.
    Abellana, R.
    Duran, E.
    Sima, A.
    Sanchez, M. J.
    Nkogo, P. R.
    Nguema, R.
    Untoria, M. D.
    Echeverria, M. A.
    Ardevol, M. M.
    de Jimenez Anta, M. T.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2006, 11 (07) : 1082 - 1091
  • [44] Evidence for macrofilaricidal activity of ivermectin against female Onchocerca volvulus:: further analysis of a clinical trial in the Republic of Cameroon indicating two distinct killing mechanisms
    Duke, BOL
    PARASITOLOGY, 2005, 130 : 447 - 453
  • [45] Prenatal immune priming in onchocerciasis -: Onchocerca volvulus-specific cellular responsiveness and cytokine production in newborns from infected mothers
    Soboslay, PT
    Geiger, SM
    Drabner, B
    Banla, M
    Batchassi, E
    Kowu, LA
    Stadler, A
    Schulz-Key, H
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1999, 117 (01): : 130 - 137
  • [46] Impaired antibody responses and loss of reactivity to Onchocerca volvulus antigens by HIV-seropositive onchocerciasis patients
    Tawill, SA
    Gallin, M
    Erttmann, KD
    Kipp, W
    Bamuhiiga, J
    Buttner, DW
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1996, 90 (01) : 85 - 89
  • [47] Interruption of the transmission of Onchocerca volvulus in the Kashoya-Kitomi focus, western Uganda by long-term ivermectin treatment and elimination of the vector Simulium neavei by larviciding
    Lakwo, T.
    Garms, R.
    Wamani, J.
    Tukahebwa, E. M.
    Byamukama, E.
    Onapa, A. W.
    Tukesiga, E.
    Katamanywa, J.
    Begumisa, S.
    Habomugisha, P.
    Oguttu, D.
    Byamukama, E.
    Richards, F.
    Unnasch, T. R.
    Katabarwa, M.
    ACTA TROPICA, 2017, 167 : 128 - 136
  • [48] Onchocerca volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 mg moxidectin or 150 μg/kg ivermectin: results of a randomized double-blind Phase 3 trial in the Democratic Republic of the Congo, Ghana and Liberia
    Kanza, Eric M.
    Nyathirombo, Amos
    Larbelee, Jemmah P.
    Opoku, Nicholas O.
    Bakajika, Didier K.
    Howard, Hayford M.
    Mambandu, Germain L.
    Nigo, Maurice M.
    Wonyarossi, Deogratias Ucima
    Ngave, Francoise
    Kennedy, Kambale Kasonia
    Kataliko, Kambale
    Bolay, Kpehe M.
    Attah, Simon K.
    Olipoh, George
    Asare, Sampson
    Mumbere, Mupenzi
    Vaillant, Michel
    Halleux, Christine M.
    Kuesel, Annette C.
    PARASITES & VECTORS, 2024, 17 (01)
  • [49] Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial
    Opoko, Nicholas O.
    Bakajika, Didier K.
    Kanza, Eric M.
    Howard, Hayford
    Mambandu, Germain L.
    Nyathirombo, Amos
    Nigo, Maurice M.
    Kasonia, Kambale
    Masembe, Safari L.
    Mumbere, Mupenzi
    Kataliko, Kambale
    Larbelee, Jemmah P.
    Kpawor, Mawolo
    Bolay, Kpehe M.
    Bolay, Fatorma
    Asare, Sampson
    Attah, Simon K.
    Olipoh, George
    Vaillant, Michel
    Halleux, Christine M.
    Kuesel, Annette C.
    LANCET, 2018, 392 (10154): : 1207 - 1216